Alphagan: profile and news

Fitch Places Allergan's Ratings on Rating Watch Negative  Nov 15, 2005
Fitch's concern regarding revenue concentration in the current product portfolio, with reliance on sales of the Botox and Alphagan products, is addressed by ... - Business Wire (press release),

Allergan Receives Positive Opinions for COMBIGAN(TM) from 21 ...  Sep 28, 2005
28, 2005--Allergan, Inc. (NYSE:AGN) today announced that it received positive opinions for COMBIGAN(TM), Allergan's ALPHAGAN(R)/timolol combination product for ... - Business Wire (press release),

FDA Approvals: Aceon, 0.1% Alphagan P, Namenda Oral Solution  Aug 25, 2005
19, the FDA approved a 0.1% formulation of brimonidine tartrate ophthalmic solution (Alphagan P, made by Allergan, Inc.) for lowering intraocular pressure (IOP ... - Medscape (subscription)

New Formulation of Allergan's ALPHAGAN(R) P Receives US FDA ...  Aug 19, 2005
19, 2005--Allergan, Inc. (NYSE:AGN) today announced it has received approval from the US Food and Drug Administration (FDA) to market ALPHAGAN(R) P ... - Business Wire (press release),

Allergan Bolsters Generic Defense Strategy  Aug 22, 2005
...nyse: AGN - news - people ) after the company said it received US Food and Drug Administration approval to market a new formulation of its Alphagan P glaucoma ... - Forbes

Eye On Stocks For Monday, Aug. 22  Aug 19, 2005
Allergan (nyse: AGN - news - people ) said it received US Food and Drug Administration approval to market a new formulation of its Alphagan P glaucoma treatment ... - Forbes

Stocks to Watch Northwest, Merck, HJ Heinz  Aug 20, 2005
Terms weren't disclosed. Allergan Inc. (AGN: news, chart, profile) said that a new formulation of its Alphagan treatment, used to lower intraocular pressure in ... - MarketWatch

Movers & Shakers  Aug 22, 2005
Allergan Inc. (AGN: news, chart, profile) said that a new formulation of its Alphagan treatment, used to lower intraocular pressure in patients with open-angle ... - MarketWatch

Today's Orange County business briefs  Aug 20, 2005
The new version of Alphagan reduces the concentration of the solution by half without decreasing its performance, thus reducing a patient's exposure to the drug ... - OCRegister (subscription),

Northwest, Merck, HJ Heinz, Motorola, more  Aug 20, 2005
Terms weren't disclosed. Allergan Inc. (AGN) said that a new formulation of its Alphagan treatment, used to lower intraocular pressure in patients with open ... - Investor's Business Daily (subscription)

Allergan Reports Second Quarter Operating Results and Increases ...  Jul 27, 2005
The FDA issued an approvable letter for Alphagan(R) Z (brimonidine tartrate ophthalmic solution) for the lowering of intraocular pressure in patients with ... - Business Wire (press release)

Fitch Affirms Allergan's 'A+' Rating; Outlook Stable  Jul 18, 2005
Fitch is concerned with revenue concentration in the Botox and Alphagan products, which collectively represented 47.5% of total revenues for the LTM period at ... - dBusinessNews Chicago (press release)

Allergan Reports Second Quarter Operating Results and Increases ...  Jul 27, 2005
The FDA issued an approvable letter for Alphagan(R) Z (brimonidine tartrate ophthalmic solution) for the lowering of intraocular pressure in patients with ... - Business Wire (press release),

Fitch Affirms Allergan's 'A+' Rating; Outlook Stable  Jul 18, 2005
Fitch is concerned with revenue concentration in the Botox and Alphagan products, which collectively represented 47.5% of total revenues for the LTM period at ... - dBusinessNews Chicago (press release),

JPMorgan Upgrades Allergan  Jun 2, 2005
Developments and FDA discussions relating a newer version of the company's glaucoma treatment Alphagan, which is expected to get FDA approval soon, and Combigan ... - Forbes

Allergan Reports First Quarter Operating Results and Increases ...  Apr 27, 2005
The US Food and Drug Administration (FDA) issued an approvable letter for Combigan(TM), Allergan's Alphagan(R)/ timolol combination product for the ... - Business Wire,

Anne Loomis Joins Torre Lazur McCann West  08 Apr 2005
...she was in charge of Lucentis, Genentech's monoclonal antibody, and the Allergan glaucoma franchise, including the global launches of Alphagan® and Lumigan®. ... - Yahoo News (press release)

Although specific drug interaction studies have not been conducted with ALPHAGAN^® P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. Alpha-agonists, as a class, may reduce pulse and blood pressure. Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.

Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with ALPHAGAN^® P in humans can lead to resulting interference with the IOP lowering effect. No data on the level of circulating catecholamines after ALPHAGAN^® P administration are available. Caution, however, is advised in patients taking tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.